Eleanor Stride, OBE, FREng is the Statutory Professor of Biomaterials in the Departments of Engineering Science and the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences. She specialises in the fabrication of nano and microscale devices for targeted drug delivery.
She obtained her BEng and PhD in Mechanical Engineering from UCL where she subsequently appointed to a Royal Academy of Engineering Research Fellowship. In 2011 she joined the Oxford Institute of Biomedical Engineering becoming a full Professor in 2014.
Eleanor’s work has been recognized through the award of a Philip Leverhulme prize, The Royal Society Interface Award, Engineering Medal at the Parliamentary Science, Engineering & Technology for Britain awards, Acoustical Society of America Bruce Lindsay Award (2013), IET AF Harvey prize (2015), Blavatnik Awards for Young Scientists (2020). In 2016 and 2019 she was nominated as one of the top 100 most influential Women in Engineering and in 2017 was made a fellow of the Royal Academy of Engineering.
https://en.wikipedia.org/wiki/Eleanor_Stride
https://www.ndorms.ox.ac.uk/team/eleanor-stride
https://eng.ox.ac.uk/people/eleanor-stride/
https://www.linkedin.com/in/eleanor-stride-53b91515/?originalSubdomain=uk
Professor Stride discussed the history and development of cancer therapy from its origins in Ancient Egypt – when surgery was the only option to remove a tumour, to the more recent developments of radiotherapy and chemotherapy. She ended the talk by looking at present-day clinical trials that aim to harness the body’s own immune system to eliminate disease (immunotherapy).
helen the hare 